8:00 am Registration & Morning Coffee
8:50 am Chair’s Opening Remarks
Emerging Non-Coding RNA Therapeutics: Current Findings & Looking into the Future
9:00 am
Breakfast Panel: What does the Future Landscape of Emerging Non-Coding RNA Therapeutics Look Like?
Moderator:
Ranjan Perera
Director RNA Center & Associate Professor, Johns Hopkins University
Panelits:
Synopsis
- What are considered as emerging non-coding RNA therapeutics and where is innovation expected to come from?
- Outlining the advantages and opportunities that emerging long non-coding RNA therapeutics and microRNAs offer
- Discussing what the next steps are in the research to accelerate these novel therapeutics into the clinic
10:00 am Morning Break & Speed Networking
Synopsis
This session is the perfect opportunity to get face-to-face time with the key opinion leaders in non-coding RNAs.
Establish meaningful business relationships to build upon for the rest of the conference and gain individual insight into the pioneering work ongoing.
Nucelic Acid Targeting Approaches for Improved Target Validation of Non-Coding RNA Therapeutics
11:00 am Therapeutic Targeting of LncRNAs with Next Generation Antisense Oligonucleotides in Cancer
Synopsis
- Discussing the potential of targeting lncRNAs with next generation antisense drug for cancer
- The technology also enables the rapid target validation of candidate lncRNAs in vitro and in vivo with the FLAME discovery engine
- Identification and selection of clinical candidate Malat1rx for the treatment of cancer
11:30 am Targeting Immune Priming LncRNAs (IPLs) with Antisense Oligonucleotides to Treat Inflammatory Diseases
Synopsis
- Lemba has developed the MOSAICTM machine learning AI-engine to identify ASO lead candidates
- Lead ASOs reduced systemic inflammation and decreased mortality in a humanized model of acute inflammation
- Targeting IPLs reduced inflammation-mediated choroidal neovascularisation in a porcine model of wet age-related macular degeneration (AMD)
12:00 pm High-Throughput Discovery & Characterization of Long Non-Coding RNA Targets Using Arrayed CRISPR Screens
Synopsis
- Arrayed CRISPR-interference for lncRNA target knockdown
- Cellular and molecular phenotyping
- Live cell imaging and high-throughput RNA-sequencing
12:30 pm Networking Lunch
Expanding Long Non-Coding RNAs Druggability Beyond Oncology
1:30 pm Transformational RNA-Guided Programmable Therapeutics to Target Disease-Causing Cell-States
Synopsis
- LncRNAs as druggable ‘information processing units’ for programming cell-states
- High priority lncRNA target discovery in fibrosis associated cell-state changes
- Considerations for lncRNA ‘druggability’
2:00 pm A LncRNA-Based Treatment of Hypertrophic Cardiomyopathies
Synopsis
- Delving into lncRNA-based treatment of hypertrophic cardiomyopathies
- Optimized delivery of lncRNAs to cardiac muscle
- Exploring mode of action studies
2:30 pm Afternoon Networking Break & Poster Session
Identification & Selection of Potent Long Non-Coding Therapeutic Targets & Clinical Candidates in Oncology
3:30 pm Advancing Novel Target & Drug Discovery Engine to Drug Non-Coding RNAs
Synopsis
- Non-coding RNAs and their interacting proteins represent a vast class of therapeutic targets
- NextRNA leverages a proprietary target validation platform to identify and prioritize long non-coding RNA therapeutic programs
- Developing small molecules to specifically disrupt ncRNA-protein interactions
4:00 pm The Therapeutic Potential of the LncRNA lnc-HLX-2-7 in Group 3 Medulloblastomas in Children
Synopsis
- Delving into medulloblastoma (MB), an aggressive brain tumor that predominantly affects children
- Identifying a novel oncogenic lncRNA, lnc-HLX-2-7, as a potential therapeutic target in group 3 MBs
- Analyzing the importance of the lnc-HLX-2-7-HLX-MYC axis in regulating group 3 MB progression
- Providing a strong rationale for using lnc-HLX-2-7 as a specific and potent therapeutic target for the group 3 MBs in children
4:30 pm Targeting LncRNAs to Impact Breast Cancer Progression
Synopsis
- LncRNA misregulation is associated with a wide range of cancer types
- LncRNAs represent a relatively overlooked class of therapeutic targets
- Nucleic acid therapeutic targets and nucleic acid therapeutics